12:16 PM
 | 
Feb 16, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BB3: Ph II GUARD started

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >